Close
FINDING CURES TOGETHER<sup>SM</sup>

​AACR Cancer Prevention Summit: Feb. 3-5, 2016

Shaping the Future of Cancer Prevention: A Roadmap for Integrative Cancer Science and Public Health

Throughout its proud history of setting the research agenda for the cancer community, the AACR has been instrumental in making cancer prevention a major focus of that agenda. From the prohibition of smoking in session rooms (1969) to the first major session on prevention (1979) to the presentation of the AACR-ACS Award for Research Excellence in Cancer Epidemiology and Prevention (1992), the AACR Annual Meeting has provided a forum for pioneering cancer prevention science. As the needs of the field have expanded, the AACR has acted boldly to meet those needs, creating the first major annual meeting devoted to Frontiers in Cancer Prevention (2002), establishing an award for Outstanding Achievement in Cancer Prevention Research, and launching the first scientific journal dedicated exclusively to prevention (Cancer Prevention Research, 2008).

The field of cancer prevention is at an exciting stage, and once more the AACR is taking the lead to foster effective collaborations, develop synergies, and integrate specialties to benefit the cancer research community. From Feb. 3-5, 2016, the AACR will be hosting a summit dedicated to cancer prevention, co-chaired by Ernest T. Hawk, MD, MPH and Scott M. Lippman, MD, and supported by Susan G. Komen, Janssen Pharmaceuticals, and Bristol-Myers Squibb.

The principal goal of this special event is to convene a diverse array of 70 experts representing all areas of cancer prevention to discuss the current excitement and future promise for this essential component of cancer research, while simultaneously identifying actions that the AACR can take to better support the field. The summit will feature remarks from the National Cancer Institute, presented by Acting Director Douglas R. Lowy, MD, FAACR, and a keynote lecture on the future of cancer prevention by Elizabeth H. Blackburn, PhD, AACR Past President, Fellow of the AACR Academy, and Nobel Laureate.

Major scientific areas to be covered at the summit will include, but are not limited to: basic science of premalignancy and prevention; biomarkers, early detection, and screening; cancer in minority populations and cancer health disparities; cancer interception; clinical epidemiology, lifestyle, and environmental risk factors; dissemination and implementation science; energy balance, chronic inflammation, and the microbiome; HPV-related cancers and vaccines; molecular epidemiology, cancer genetics, and predisposition genes; non-viral vaccines and immunoprevention; precision cancer prevention; precision molecular diagnostics; quantitative sciences; and survivorship and energetics.

Summit Co-Chairpersons

  • Ernest T. Hawk, MD, MPH
    The University of Texas MD Anderson Cancer Center, Houston, Texas

  • Scott M. Lippman, MD
    UCSD Moores Cancer Center, La Jolla, California

Summit Participants

  • Cory Abate-Shen, PhD
    Columbia University Medical Center, New York, New York

  • Adriana Albini, PhD
    Fondazione MultiMedica Onlus, Milan, Italy

  • Carolyn R. Aldigé
    Prevent Cancer Foundation, Alexandria, Virginia

  • Sanjeev Arora, MD
    University of New Mexico, Albuquerque, New Mexico

  • Janine Arts, PhD
    Janssen Research & Development, Beerse, Belgium

  • Alberto Bardelli, PhD
    IRCC-University of Turin, Medical School, Candiolo, Italy

  • Jennifer E. Beane, PhD
    Boston University School of Medicine, Boston, Massachusetts

  • Elizabeth H. Blackburn, PhD, FAACR
    The Salk Institute, La Jolla, California

  • Powel H. Brown, MD, PhD
    The University of Texas MD Anderson Cancer Center, Houston, Texas

  • Andrew T. Chan, MD, MPH
    Massachusetts General Hospital, Boston, Massachusetts

  • Stephen J. Chanock, MD
    National Cancer Institute, Bethesda, Maryland

  • Graham A. Colditz, MD, DrPH, MPH
    Washington University, St. Louis, Missouri

  • Alberto F. Costa, MD
    European School of Oncology, Milan, Italy

  • Andrew J. Dannenberg, MD
    Weill Cornell Medical College, New York, New York

  • Nancy E. Davidson, MD
    University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, Pennsylvania

  • Phillip A. Dennis, MD, PhD
    AstraZeneca Pharmaceuticals, Gaithersburg, Maryland

  • Mary L. Disis, MD
    University of Washington, Seattle, Washington

  • Zigang Dong, MD, DrPH
    University of Minnesota, Austin, Minnesota

  • Raymond N. DuBois, MD, PhD, FAACR
    The Biodesign Institute, Arizona State University, Tempe, Arizona

  • Hashem B. El-Serag, MD, MPH
    Baylor College of Medicine, Houston, Texas

  • Ruth D. Etzioni, PhD
    Fred Hutchinson Cancer Research Center, Seattle, Washington

  • Olivera J. Finn, PhD
    University of Pittsburgh, Pittsburgh, Pennsylvania

  • Leslie G. Ford, MD
    National Cancer Institute, Bethesda, Maryland

  • Judy E. Garber, MD, MPH, FAACR
    Dana-Farber Cancer Institute, Boston, Massachusetts

  • Maura L. Gillison, MD, PhD
    Ohio State University, Columbus, Ohio

  • Anna R. Giuliano, PhD
    Moffitt Cancer Center, Tampa, Florida

  • J. Silvio Gutkind, PhD
    UCSD Moores Cancer Center, La Jolla, California

  • William N. Hait, MD, PhD, FAACR
    Janssen Research & Development, LLC, Raritan, New Jersey

  • Stephen S. Hecht, PhD
    University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota

  • Waun Ki Hong, MD, FAACR
    The University of Texas MD Anderson Cancer Center, Houston, Texas

  • Nancy Hopkins, PhD
    Massachusetts Institute of Technology, Cambridge, Massachusetts

  • Chanita Hughes Halbert, PhD
    Medical University of South Carolina, Charleston, South Carolina

  • Melinda L. Irwin, PhD
    Yale Cancer Center, New Haven, Connecticut

  • Elizabeth M. Jaffee, MD
    Johns Hopkins University, Baltimore, Maryland

  • Lee W. Jones, PhD
    Memorial Sloan Kettering Cancer Center, New York, New York

  • Thomas W. Kensler, PhD
    University of Pittsburgh, Pittsburgh, Pennsylvania

  • William Klein, PhD
    National Cancer Institute, Bethesda, Maryland

  • Barnett S. Kramer, MD, MPH
    National Cancer Institute, Bethesda, Maryland

  • J. Jack Lee, PhD, DDS
    The University of Texas MD Anderson Cancer Center, Houston, Texas

  • Paul J. Limburg, MD, MPH
    Mayo Clinic College of Medicine, Rochester, Minnesota

  • Douglas R. Lowy, MD, FAACR
    National Cancer Institute, Bethesda, Maryland

  • Anirban Maitra, MBBS
    The University of Texas MD Anderson Cancer Center, Houston, Texas

  • Maria Elena Martinez, PhD, MPH
    UCSD Moores Cancer Center, La Jolla, California

  • Worta McCaskill-Stevens, MD, MS
    National Cancer Institute, Rockville, Maryland

  • Electra D. Paskett, PhD, MPH
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Ruth E. Patterson, PhD
    UCSD Moores Cancer Center, La Jolla, California

  • Michael N. Pollak, MD
    McGill University and Jewish General Hospital, Montreal, Quebec, Canada

  • Amelie G. Ramirez, DrPH
    The University of Texas Health Science Center at San Antonio, San Antonio, Texas

  • Timothy R. Rebbeck, PhD
    Dana-Farber Cancer Institute, Boston, Massachusetts

  • Brian J. Reid, MD, PhD
    Fred Hutchinson Cancer Research Center, Seattle, Washington

  • Kimberly A. Sabelko, PhD
    Susan G. Komen, Dallas, Texas

  • N. Jewel Samadder, MD
    University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

  • Paul A. Scheet, PhD
    The University of Texas MD Anderson Cancer Center, Houston, Texas

  • John T. Schiller, PhD
    National Cancer Institute, Bethesda, Maryland

  • Kathryn H. Schmitz, PhD, MPH
    University of Pennsylvania, Philadelphia, Pennsylvania

  • Victoria L. Seewaldt, MD
    City of Hope, Duarte, California

  • Thomas A. Sellers, PhD, MPH
    Moffitt Cancer Center & Research Institute, Tampa, Florida

  • David Sidransky, MD
    Johns Hopkins Medical Institutes, Baltimore, Maryland

  • Celette S. Skinner, PhD
    The University of Texas Southwestern Medical Center, Dallas, Texas

  • Kara Smigel Croker
    National Cancer Institute, Bethesda, Maryland

  • Avrum Spira, MD
    Boston University School of Medicine, Boston, Massachusetts

  • Eva Szabo, MD
    National Cancer Institute, Bethesda, Maryland

  • Giorgio Trinchieri, MD
    National Cancer Institute, Bethesda, Maryland

  • Cornelia M. Ulrich, PhD
    University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

  • Eduardo Vilar-Sanchez, MD, PhD
    The University of Texas MD Anderson Cancer Center, Houston, Texas

 Top of page